

Gabe S Sonke

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1479922/gabe-s-sonke-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

101
papers

7,721
citations

31
h-index

87
g-index

107
ext. papers

10,146
ext. citations

8.5
avg, IF

5.46
L-index

#	Paper	IF	Citations
101	Analytical and pharmacological consequences of the in vivo deamidation of trastuzumab and pertuzumab.. <i>Analytical and Bioanalytical Chemistry</i> , 2022 , 414, 1513-1524	4.4	2
100	Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.. <i>Journal of the National Cancer Institute</i> , 2022 ,	9.7	1
99	Socioeconomic status and its relation with breast cancer recurrence and survival in young women in the Netherlands.. <i>Cancer Epidemiology</i> , 2022 , 77, 102118	2.8	1
98	Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus.. <i>Gynecologic Oncology Reports</i> , 2022 , 39, 100945	1.3	0
97	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 942-950	59.2	18
96	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101536	2.2	2
95	Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance.. <i>Npj Breast Cancer</i> , 2022 , 8, 60	7.8	1
94	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.. <i>Lancet Oncology, The</i> , 2021 ,	21.7	16
93	Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1506-1514	9.7	2
92	Ribociclib plus fulvestrant in the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 93-106	3.5	3
91	Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 185, 817-830	4.4	0
90	Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study. <i>Breast Cancer Research and Treatment</i> , 2021 , 185, 205-214	4.4	8
89	Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkab010	4.6	5
88	Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review. <i>JAMA Oncology</i> , 2021 , 7, 1231-1238	13.4	2
87	Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2021 , 78, 86-86	4.6	1
86	Improved risk estimation of locoregional recurrence, secondary contralateral tumors and distant metastases in early breast cancer: the INFLUENCE 2.0 model. <i>Breast Cancer Research and Treatment</i> , 2021 , 189, 817-826	4.4	1
85	Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 888-892	3.5	23

84	Adjuvant chemotherapy in small node-negative triple-negative breast cancer. <i>European Journal of Cancer</i> , 2020 , 135, 66-74	7.5	7
83	Prognosis of acute coronary syndromes after radiotherapy for breast cancer. <i>Radiotherapy and Oncology</i> , 2020 , 146, 110-117	5.3	3
82	High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 528-534	13.4	11
81	Applying Risk-Based Follow-Up Strategies on the Dutch Breast Cancer Population: Consequences for Care and Costs. <i>Value in Health</i> , 2020 , 23, 1149-1156	3.3	0
80	Heart failure after treatment for breast cancer. <i>European Journal of Heart Failure</i> , 2020 , 22, 366-374	12.3	14
79	Myocardial dysfunction in long-term breast cancer survivors treated at ages 40-50 years. <i>European Journal of Heart Failure</i> , 2020 , 22, 338-346	12.3	11
78	Moderators of Exercise Effects on Cancer-related Fatigue: A Meta-analysis of Individual Patient Data. <i>Medicine and Science in Sports and Exercise</i> , 2020 , 52, 303-314	1.2	20
77	Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 514-524	59.2	251
76	Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. <i>European Journal of Cancer</i> , 2020 , 139, 59-67	7.5	3
75	Prognostic factors in patients with oligometastatic breast cancer - A systematic review. <i>Cancer Treatment Reviews</i> , 2020 , 91, 102114	14.4	9
74	Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1928-1934	3.5	2
73	Validation of the online prediction model CancerMath in the Dutch breast cancer population. <i>Breast Cancer Research and Treatment</i> , 2019 , 178, 665-681	4.4	2
72	Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore. <i>Clinical Cancer Research</i> , 2019 , 25, 4985-4992	12.9	8
71	Complex challenges for patients with protracted incurable cancer: an ethnographic study in a comprehensive cancer centre in the Netherlands. <i>BMJ Open</i> , 2019 , 9, e024450	3	3
70	Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2041-2050	2.2	25
69	Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on. <i>Cancer</i> , 2019 , 125 Suppl 24, 4587-4593	6.4	14
68	Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data. <i>British Journal of Sports Medicine</i> , 2019 , 53, 812	10.3	43
67	Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. <i>International Journal of Cancer</i> , 2019 , 144, 263-272	7.5	56

66	Global cancer control: responding to the growing burden, rising costs and inequalities in access. <i>ESMO Open</i> , 2018 , 3, e000285	6	98
65	Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 1363-1364	59.2	52
64	Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 230-240	59.2	627
63	Enrichment of high-grade tumors in breast cancer gene expression studies. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 327-335	4.4	3
62	Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018 , 167, 659-669	4.4	45
61	Cost-utility and cost-effectiveness of physical exercise during adjuvant chemotherapy. <i>European Journal of Health Economics</i> , 2018 , 19, 893-904	3.6	24
60	Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. <i>British Journal of Cancer</i> , 2018 , 119, 408-418	8.7	31
59	Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 127-134	4.4	62
58	Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery. <i>Gynecologic Oncology</i> , 2018 , 148, 56-61	4.9	11
57	Recruitment to and pilot results of the PACES randomized trial of physical exercise during adjuvant chemotherapy for colon cancer. <i>International Journal of Colorectal Disease</i> , 2018 , 33, 29-40	3	19
56	Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2465-2472	2.2	435
55	Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial. <i>BMC Cancer</i> , 2018 , 18, 1146	4.8	19
54	Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 1630-1640	21.7	113
53	Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 1190-1200	9.7	50
52	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 2495-2505	59.2	1061
51	Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. <i>European Journal of Cancer</i> , 2017 , 74, 47-54	7.5	16
50	Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 112, 198-207	7	18
49	MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2017 , 164, 99-106	4.4	22

48	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. <i>Drugs</i> , 2017 , 77, 1313-1336	12.1	25
47	Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs. <i>Cancer Treatment Reviews</i> , 2017 , 52, 91-104	14.4	272
46	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1274-1284	21.7	913
45	Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. <i>BMJ Open</i> , 2017 , 7, e017842	3	7
44	Additional value of F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer. <i>Cancer Imaging</i> , 2017 , 17, 15	5.6	5
43	Doctors' reports about palliative systemic treatment: A medical record study. <i>Palliative Medicine</i> , 2017 , 31, 239-246	5.5	2
42	Herkennen van inflammatoir mammacarcinoom. <i>Huisarts En Wetenschap</i> , 2017 , 60, 404-406	0.1	1
41	Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes. <i>PLoS ONE</i> , 2017 , 12, e0176782	3.7	14
40	A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. <i>Trials</i> , 2016 , 17, 293	2.8	12
39	Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2107-14	2.2	34
38	Why do patients choose (not) to participate in an exercise trial during adjuvant chemotherapy for breast cancer?. <i>Psycho-Oncology</i> , 2016 , 25, 964-70	3.9	46
37	The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 361-71	4.4	19
36	Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4354-4361	2.2	155
35	Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. <i>Breast</i> , 2016 , 29, 153-9	3.6	22
34	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1738-1748	59.2	975
33	Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. <i>British Journal of Cancer</i> , 2015 , 113, 396-402	8.7	36
32	Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1918-27	2.2	319
31	Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology, The</i> , 2015 , 16, 1639-50	21.7	190

30	Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 627-36	4.4	30
29	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. <i>Lancet Oncology</i> , 2015 , 16, 87-97	21.7	405
28	Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. <i>Annals of Surgery</i> , 2015 , 261, 378-82	7.8	229
27	Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer. <i>Obstetrics and Gynecology International</i> , 2015 , 2015, 464123	2	15
26	Bereaved relatives' experiences during the incurable phase of cancer: a qualitative interview study. <i>BMJ Open</i> , 2015 , 5, e009009	3	7
25	Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval. <i>PLoS ONE</i> , 2015 , 10, e0120832	3.7	17
24	Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?. <i>Cureus</i> , 2015 , 7, e433	1.2	3
23	Optimising end of life care requires an individualised approach. <i>BMJ</i> , 2014 , 348, g2312	5.9	3
22	Effectiveness of chemotherapy in measurable granulosa cell tumors: a retrospective study and review of literature. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, 496-505	3.5	24
21	Guiding breast-conserving surgery in patients after neoadjuvant systemic therapy for breast cancer: a comparison of radioactive seed localization with the ROLL technique. <i>Annals of Surgical Oncology</i> , 2013 , 20, 2569-75	3.1	53
20	Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer. <i>Breast Journal</i> , 2013 , 19, 419-26	1.2	11
19	SERPINA6, BEX1, AGTR1, SLC26A3, and LAPT4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 137, 213-23	4.4	40
18	The facilitating role of chemotherapy in the palliative phase of cancer: qualitative interviews with advanced cancer patients. <i>PLoS ONE</i> , 2013 , 8, e77959	3.7	29
17	Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 136, 35-43	4.4	73
16	Design of the Physical exercise during Adjuvant Chemotherapy Effectiveness Study (PACES): a randomized controlled trial to evaluate effectiveness and cost-effectiveness of physical exercise in improving physical fitness and reducing fatigue. <i>BMC Cancer</i> , 2010 , 10, 673	4.8	41
15	A philosophical perspective supports the need for patient-outcome studies in diagnostic test evaluation. <i>Journal of Clinical Epidemiology</i> , 2009 , 62, 58-61	5.7	10
14	Poor outcomes of chronic active Epstein-Barr virus infection and hemophagocytic lymphohistiocytosis in non-Japanese adult patients. <i>Clinical Infectious Diseases</i> , 2008 , 47, 105-8	11.6	36
13	A philosophical approach to diagnostic test evaluation. <i>Annals of Internal Medicine</i> , 2007 , 146, 757; author reply 757-8	8	3

12	Lower pre-hospital case fatality after myocardial infarction creates a survival benefit for women compared with men. <i>American Journal of Cardiology</i> , 2007 , 99, 1481	3	
11	Prenatal and perinatal risk factors and testicular cancer: a hospital-based case-control study. <i>Oncology Research</i> , 2007 , 16, 383-7	4.8	29
10	Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. <i>Journal of Pathology</i> , 2004 , 202, 23-33	9.4	144
9	A method for estimating within-patient variability in maximal urinary flow rate adjusted for voided volume. <i>Urology</i> , 2002 , 59, 368-72	1.6	10
8	Proliferative activity and branching morphogenesis in the human prostate: a closer look at pre- and postnatal prostate growth. <i>Prostate</i> , 2001 , 49, 132-9	4.2	21
7	alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. <i>Journal of Urology</i> , 2001 , 165, 38-41	2.5	51
6	Intra- and inter-investigator variation in the analysis of pressure-flow studies in men with lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2000 , 19, 221-32	2.3	15
5	Variability of pressure-flow studies in men with lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2000 , 19, 637-51; discussion 651-6	2.3	28
4	HIGH ENERGY TRANSURETHRAL MICROWAVE THERMOTHERAPY FOR THE TREATMENT OF PATIENTS IN URINARY RETENTION. <i>Journal of Urology</i> , 2000 , 163, 1457-1460	2.5	24
3	PREDICTION OF BLADDER OUTLET OBSTRUCTION IN MEN WITH LOWER URINARY TRACT SYMPTOMS USING ARTIFICIAL NEURAL NETWORKS. <i>Journal of Urology</i> , 2000 , 163, 300-305	2.5	23
2	Low reproducibility of maximum urinary flow rate determined by portable flowmetry. <i>Neurourology and Urodynamics</i> , 1999 , 18, 183-91	2.3	23
1	Diagnostic research in benign prostatic hyperplasia--from sensitivity to neural networks. <i>Current Opinion in Urology</i> , 1999 , 9, 31-7	2.8	3